Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2019-06-11
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 13
- Registration Number
- NCT02390934
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Transpulmonary Thermodilution Using an Implented Central Venous Access Port
Completed
- Conditions
- First Posted Date
- 2015-02-06
- Last Posted Date
- 2016-06-09
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 20
- Registration Number
- NCT02357953
- Locations
- 🇫🇷
Gustave Roussy Cancer Campus Grand Paris, Villejuif, Val de Marne, France
Sequential Analysis in Patients With an Hemopathy
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 246
- Registration Number
- NCT02260739
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France
Randomized, Double Blind, Efficacy Study of Escitalopram in ENT Cancer Patients Suffering From Emotional Distress
- First Posted Date
- 2014-09-22
- Last Posted Date
- 2016-06-10
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 38
- Registration Number
- NCT02246244
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2014-09-08
- Last Posted Date
- 2018-07-23
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 250
- Registration Number
- NCT02233049
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2018-07-23
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 80
- Registration Number
- NCT02230176
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Dose Escalation of Velcade Daily Dose in Patients With Solid Tumors
- First Posted Date
- 2014-08-19
- Last Posted Date
- 2016-03-25
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 18
- Registration Number
- NCT02220049
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France
Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2016-01-26
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 30
- Registration Number
- NCT02217956
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France
Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid Tumors
Phase 1
- Conditions
- Interventions
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2016-02-10
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 42
- Registration Number
- NCT02215720
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France
Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-05-06
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 110
- Registration Number
- NCT02131480
- Locations
- 🇫🇷
Gustave Roussy Cancer Campus Grand Paris, Villejuif, Val de Marne, France
© Copyright 2024. All Rights Reserved by MedPath